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The final section ofthe volume is devoted to discussions ofregulatory T circuits in
an effort to consolidate the experimental data into an understanding ofthe physio-
logic control of the immune response. Employing the concept of "id^" and "id" T
regulatory cells (for those T lymphocytes bearing idiotypes either identical or
complementary to that of the B cell being controlled), Herzenberg et al. have
proposed the concept of the core regulatory circuit. In it, two sets of helper T cells
and two sets of suppressor T cells modulate each other in a cyclic fashion, the
outcome of which determines whether a given B lymphocyte is helped or suppressed.
Presumably all soluble factor- and macrophage-mediated interactions affecting B cell
response do so by altering the equilibrium of this four-cell circuit. As with Jerne's
original formulation of a network hypothesis to explain immune regulation [2], such
a theory represents a good framework from which to ask future questions and to
build a more comprehensive model of lymphocyte interactions.
The constantly changing nature of cellular immunology makes it difficult for any
one book to cover the field adequately. However, the papers in this volume, which
are uniformly well written, present new data as well as summarize years of previous
work by most of the leading laboratories in the area. As such, this volume represents
an excellent, fairly up-to-date review of regulatory T cells, as well as a useful guide to
new work in this rapidly emerging field.
1. Gowans et al: Nature 196:651, 1962
2. Jerne NK: Ann Immunol (Paris) 125:373, 1974
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The Second Annual Bristol-Myers Symposium on Cancer Research was truly a
whirlwind affair. Hosted by the Yale University Department of Pharmacology and
the Developmental Therapeutics Program of the Comprehensive Cancer Center,
twenty-nine internationally known scientists presented papers to nearly five hundred
participants over two days (November 8-9, 1979) at the Sheraton-Park Plaza Hotel
in New Haven, CT. The effects of such a program on this reviewer were exhilarating
yet unsatisfying. Limited to twenty minutes for presentation and a fifteen-minute
panel discussion at the end of a session, each lecturer worked crisply to lay down the
fundamentals of the research and hoped to break some new ground before time
expired. Any temptation to pause and reflect must be stronglysuppressed duringthis
type of rapid-fire delivery, and therein lies the rub. Needless to say, this handsome
volume of the proceedings is a welcome, detailed account of this impressive
symposium and stands on its own as an important compendium of some of the
current frontiers of cancer research.
The book contains twenty-eight papers (one speaker failed to contribute) which are
grouped into seven parts, following the outline of the symposium. Part I, entitled
"Alkylating Agents," begins with discussions of the mechanisms and targets of
clinically relevant drugs such as the nitrogen mustards and platinum compounds by
Drs. K.W. Kohn, J.J. Roberts, and K.R. Harrap. Particularly noteworthy in terms ofBOOK REVIEWS 315
new directions in drug design are the contributions by Dr. Sartorelli and Dr. R.H.
Abeles. Dr. Sartorelli's innovative approach to the development of bioreductive
alkylating agents as chemotherapeutic agents for hypoxic tumor cell populations and
Dr. Abeles's elegant mechanistic work on the design ofspecific "suicide inhibitors" of
important enzymes exemplify the new wave of medicinal chemistry which is rapidly
taking hold in enlightened scientific circles. Part II, "Antibiotics," deals virtually
exclusively with DNA-drug interactions. Dr. H.M. Sorbell sets down the biophysical
framework with his important work on drug intercalation, followed by Drs. S.T.
Crooke, I.H. Goldberg, and F. Hutchinson, who discuss their interestingfindings on
the molecular pharmacology of the DNA-interacting anthracyclines, neocarzinos-
tatin, and bleomycins, respectively.
Parts III and IV deal with antimetabolites. In Part III the subject of"Nucleoside
Analogs" is approached from the question of transport by Dr. A.R.P. Paterson, the
design of inhibitors of purine nucleoside phosphorylases by Dr. R.E. Parks, Jr., and
of S-adenosyl-methionine dependent enzymes by Dr. J.K. Coward. Mechanistic
work on the clinically important 5-fluorouracil is thoroughly discussed by Drs. F.
Maley and D.V. Santi. "Folate Analogs" in Part IV are discussed in terms of X-ray
binding studies to dihydrofolate reductase by Dr. R.L. Blakley, transport by Drs.
F.M. Huennekens and F.M. Sirotnack, and cellular resistance via gene amplification,
an exciting recent discovery, by Dr. Bertino. Part V, entitled "Radiation Sensitizers,"
contains good discussions of the problem of hypoxic cells in radiotherapy by Dr.
G.E. Adams and the considerations in the design of new hypoxic cells sensitizers by
Dr. J.D. Chapman.
"Membrane Targets" is the subject of Part VI. Dr. D.F.H. Wallach discusses
general considerations of plasma membranes in chemotherapy while Dr. J.C. Biedler
examines altered membrane glycoconjugates in Chinese hamster cells with acquired
drug resistance. One of the more intriguing papers by Dr. S.B. Horwitz presented
some fine studies on steganacin and taxol which are inhibitors oftubulin polymeriza-
tion to microtubules, an important constituent ofthe cytoskeleton ofeukaryotic cells.
Part VII, "Angiogenesis-Metastasis-Anticarcinogenesis-Differentiation" handles
some of the more esoteric aspects of chemotherapy. The studies on angiogenesis
inhibitors by Dr. J. Folkman, retinoids by Drs. G.L. Nicolson and M.B. Sporn, and
on differentiation by Drs. R.C. Gallo and L. Sachs are fascinating reading though
their relationships to the title of this book may seem abstruse.
Overall, the editors deserve much praise for organizing an impressive symposium
and for producing this informative volume. For those who attended the proceedings
this book will satisfy the frustration of the short presentations. For the cancer
research community in general it will be a timely collection of progress reports from
many of the leaders in diverse areas of basic cancer chemotherapy.
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The explosive advances in molecular biology are nowhere more apparent than in
the field of pituitary hormones. Within a handful of years, a- and p-melanotropin
(MSH), considered the standard pigment-inducing hormones, have been demon-